Breadcrumbs Home Investors Press Releases Press Releases Press Releases Regulatory Press Releases More Press Releases Data Year2025202420232022202120202019201820172016201520142013201220112010 2021-02-08 11:00OncoZenge has obtained a conditional approval for listing on Nasdaq First North Growth Market and publishes prospectusRead more 2021-02-02 08:00Moberg Pharma's Year-end report for the financial year 2020 to be published on February 9 - Invitation to teleconferenceRead more 2021-01-29 13:00Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex AseaRead more 2021-01-29 08:00New number of shares and votes in Moberg Pharma AB (publ)Read more 2021-01-14 16:30Moberg Pharma announces the last day of trading in BTU and the first trading day in warrantsRead more 2021-01-07 08:00OncoZenge announces issue of European Patent related to BupiZenge[®]Read more Pagination First page Previous page … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Next page Last page Press Releases Data Year2025202420232022202120202019201820172016201520142013201220112010 2020-01-22 08:00Expert evaluation clarifies Phase 3 results and provides strong support for MOB-015Read more 2020-01-14 08:30The Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares due to the redemption in 2019 of shares in Moberg Pharma AB for cashRead more 2019-12-12 08:00Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015Read more 2019-12-09 08:00Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosisRead more 2019-11-29 08:30Reclassification of series B shares in Moberg Pharma AB (publ)Read more 2019-11-19 08:00Moberg Pharma AB Interim report July - September 2019Read more Pagination First page Previous page … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 … Next page Last page
